Itraconazole prophylaxis in pediatric cancer patients receiving conventional chemotherapy or autologous stem cell transplants

Supportive Care in Cancer

Volumn 15, Issue 2, 2007, Pages 213-220

  Simon, Arne ^a   Besuden, Mette ^a   Vezmar, Sandra ^a   Hasan, Carola ^a   Lampe, Dagmar ^b   Kreutzberg, Sigrid ^b   Glasmacher, Axel ^a   Bode, Udo ^a   Fleischhack, Gudrun ^a  

^a UNIVERSITY OF BONN   (Germany)

^b Poison Information Centre   (Germany)

Author keywords

Itraconazole; Pediatric cancer patients; Pharmacokinetics

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; HYDROXYITRACONAZOLE; ITRACONAZOLE; STEROID; VINCRISTINE; VORICONAZOLE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ACUTE RESPIRATORY TRACT DISEASE; ARTICLE; ASPERGILLOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEEDING APPARATUS; FEMALE; HEMOLYSIS; HEMOLYTIC ANEMIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFANT; LOADING DRUG DOSE; LYMPHOMA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROBLASTOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; SINGLE DRUG DOSE; SOLID TUMOR; VOMITING;

ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; ASPERGILLOSIS; ASPERGILLUS; CHEMOPREVENTION; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; INFANT; ITRACONAZOLE; LEUKEMIA; LYMPHOMA; MALE; NEOPLASMS; NEUROBLASTOMA; NEUTROPENIA; PROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION;

EID: 33847378385     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-006-0125-7     Document Type: Article

References (39)

1. Wright JA, Bradfield SM, Park JR, Hawkins DS (2003) Prolonged survival after invasive aspergillosis: a single-institution review of 11 cases. J Pediatr Hematol Oncol 25(4):286-291
2. Creutzig U, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Lehrnbecher T (2004) Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol 22(21):4384-4393
3. Lin SJ, Schranz J, Teutsch SM (2001) Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 32(3):358-366
4. Humphreys H (2004) Positive-pressure isolation and the prevention of invasive aspergillosis. What is the evidence? J Hosp Infect 56(2):93-100, quiz 163
5. Manuel RJ, Kibbler CC (1998) The epidemiology and prevention of invasive aspergillosis. J Hosp Infect 39(2):95-109
6. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, Denning DW, Donnelly JP, Edwards JE et al (2002) Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 34(1):7-14
7. Simon A, Fleischhack G, Hasan C, Bode U, Engelhart S, Kramer MH (2000) Surveillance for nosocomial and central line-related infections among pediatric hematology-oncology patients. Infect Control Hosp Epidemiol 21(9):592-596
8. Cooper EE, O'Reilly MA, Guest DI, Dharmage SC (2003) Influence of building construction work on Aspergillus infection in a hospital setting. Infect Control Hosp Epidemiol 24(7):472-476
9. Denning DW, Tucker RM, Hanson LH, Stevens DA (1989) Treatment of invasive aspergillosis with itraconazole. Am J Med 86(6 Pt 2):791-800
10. Caillot D, Bassaris H, McGeer A, Arthur C, Prentice HG, Seifert W, De Beule K (2001) Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS. Clin Infect Dis 33(8):e83-e90
11. de Repentigny L, Ratelle J, Leclerc JM, Cornu G, Sokal EM, Jacqmin P, De Beule K (1998) Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. Antimicrob Agents Chemother 42(2):404-408
12. Groll AH, Wood L, Roden M, Mickiene D, Chiou CC, Townley E, Dad L, Piscitelli SC, Walsh TJ (2002) Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. Antimicrob Agents Chemother 46(8):2554-2563
13. Glasmacher A, Hahn C, Molitor E, Marklein G, Sauerbruch T, Schmidt-Wolf IG (1999) Itraconazole through concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules. Mycoses 42(11-12):591-600
14. Pandya NA, Atra AA, Riley U, Pinkerton CR (2003) Role of itraconazole in haematology/oncology. Arch Dis Child 88(3):258-260
15. Glasmacher A, Molitor E, Hahn C, Bomba K, Ewig S, Leutner C, Wardelmann E, Schmidt-Wolf IG, Mezger J et al (1998) Antifungal prophylaxis with itraconazole in neutropenic patients with acute leukaemia. Leukemia 12(9):1338-1343
16. Glasmacher A, Prentice AG (2005) Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies. J Antimicrob Chemother 56(Suppl 1):i23-i32
17. Prentice AG, Glasmacher A (2005) Making sense of itraconazole pharmacokinetics. J Antimicrob Chemother 56(Suppl 1):i17-i22
18. Gupta AK, Cooper EA, Ryder JE, Nicol KA, Chow M, Chaudhry MM (2004) Optimal management of fungal infections of the skin, hair, and nails. Am J Clin Dermatol 5(4):225-237
19. Mondal RK, Singhi SC, Chakrabarti A, MJ (2004) Randomized comparison between fluconazole and itraconazole for the treatment of candidemia in a pediatric intensive care unit: a preliminary study. Pediatr Crit Care Med 5(6):561-565
20. Singhi SC, Reddy TC, Chakrabarti A (2004) Oral itraconazole in treatment of candidemia in a pediatric intensive care unit. Indian J Pediatr 71(11):973-977
21. Groll AH (2002) Itraconazole - perspectives for the management of invasive aspergillosis. Mycoses 45(Suppl 3):48-55
22. Castagnola E, Machetti M, Bucci B, Viscoli C (2004) Antifungal prophylaxis with azole derivatives. Clin Microbiol Infect 10(Suppl 1):86-95
23. Sathiapalan RK, Al-Nasser A, El-Solh H, Al-Mohsen I, Al-Jumaah S (2002) Vincristine-itraconazole interaction: cause for increasing concern. J Pediatr Hematol Oncol 24(7):591
24. Schmitt C, Perel Y, Harousseau JL, Lemerle S, Chwetzoff E, le Moing JP, Levron JC (2001) Pharmacokinetics of itraconazole oral solution in neutropenic children during long-term prophylaxis. Antimicrob Agents Chemother 45(5):1561-1564
25. Srivatsan V, Dasgupta AK, Kale P, Datla RR, Soni D, Patel M, Patel R, Mavadhiya C (2004) Simultaneous determination of itraconazole and hydroxyitraconazole in human plasma by high-performance liquid chromatography. J Chromatogr A 1031(1-2):307-313
26. Kamaluddin M, McNally P, Breatnach F, O'Marcaigh A, Webb D, O'Dell E, Scanlon P, Butler K, O'Meara A (2001) Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies. Acta Paediatr 90(10):1204-1207
27. Penzak SR, Gubbins PO, Gurley BJ, Wang PL, Saccente M (1999) Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers. Ther Drug Monit 21(3):304-309
28. Lange D, Pavao JH, Wu J, Klausner M (1997) Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers. J Clin Pharmacol 37(6):535-540
29. Schmidt LE, Dalhoff K (2002) Food-drug interactions. Drugs 62(10):1481-1502
30. Litalien C, Theoret Y, Faure C (2005) Pharmacokinetics of proton pump inhibitors in children. Clin Pharmacokinet 44(5):441-466
31. Steinbach WJ (2005) Antifungal agents in children. Pediatr Clin North Am 52(3):895-915, viii
32. Foot AB, Veys PA, Gibson BE (1999) Itraconazole oral solution as antifungal prophylaxis in children undergoing stem cell transplantation or intensive chemotherapy for haematological disorders. Bone Marrow Transplant 24(10):1089-1093
33. Groll AH, Kolve H (2004) Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy. Eur J Clin Microbiol Infect Dis 23(4):256-270
34. Maertens J, Boogaerts M (2005) The place for itraconazole in treatment. J Antimicrob Chemother 56(Suppl 1):i33-i38
35. Warris A, Weemaes CM, Verweij PE (2002) Multidrug resistance in Aspergillus fumigatus. N Engl J Med 347(26):2173-2174
36. Marr KA, Crippa F, Leisenring W, Hoyle M, Boeckh M, Balajee SA, Nichols WG, Musher B, Corey L (2004) Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 103(4):1527-1533
37. Yuan R, Flockhart DA, Balian JD (1999) Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam. J Clin Pharmacol 39(11):1109-1125
38. Bashir H, Motl S, Metzger ML, Howard SC, Kaste S, Krasin MP, Hudson MM (2006) Itraconazole-enhanced chemotherapy toxicity in a patient with Hodgkin lymphoma. J Pediatr Hematol Oncol 28(1):33-35
39. Marr KA, Leisenring W, Crippa F, Slattery JT, Corey L, Boeckh M, McDonald GB (2004) Cyclophosphamide metabolism is affected by azole antifungals. Blood 103(4):1557-1559